27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
The US Food and Drug Administration (FDA) on Friday approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 28 September 2024
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The Parkinson’s disease (PD) market is expected to almost triple in sales in the seven major markets (7MM: The USA, France, Germany, Spain, Italy, the UK, and Japan) by 2029, rising from $4 billion in 2021 to $11.5 billion in 2029 at an impressive 12.6% compound annual growth rate (CAGR). 11 August 2021
Raman Sehgal, the founder of ramarketing, provides an Expert View on how pharmaceutical and life sciences businesses can market themselves in the post-pandemic environment. 10 August 2021
US biotech Seagen and Chinese biopharma RemeGen have announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody-drug conjugate (ADC). 10 August 2021
German biotech BioNTech saw its shares close up 15% at $447.23 on Monday, after it provided an update on its corporate progress and reported financial results for the second quarter ended June 30, 2021. 10 August 2021
Shares of Canada’s Liminal BioSciences shot up nearly 28% to $3.65 by close of trading on Monday, after it announced that, its subsidiary Prometic Biotherapeutics (PBT) has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105 million. 10 August 2021
US biotech bluebird bio yesterday reported financial results and business highlights for the second quarter ended June 30, 2021, which failed to impress investors, so the stock tumbled 27.5% to $18.16 by close of trading. 10 August 2021
The Russian government is considering a further tightening of public procurements of drugs for state needs by introducing the “second extra” principle, when the application of a Russian company that failed to localize the production of raw materials within the country will be rejected, according to recent statements made by some senior state officials and some local media reports. 10 August 2021
Russian pharmaceutical manufacturers have begun to compete for the production of generics based on bevacizumab, marketed by Swiss pharma giant Roche as Avastin, one of the most expensive and demanded cancer treatments, for which the value of state purchases currently exceeds 10 billion roubles ($136 million) a year, reports The Pharma Letter’s local correspondent. 10 August 2021
Australia’s Therapeutic Goods Administration (TGA) has granted provisional registration to the COVID-19 Vaccine Moderna in Australia for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 18 years of age and older, with the news sending the vaccine’s producer. 10 August 2021
A self-styled pioneer that promises to develop and deliver innovative medicines to patients at radically lower prices, is to raise up to $1.8 billion via a combination with special purpose acquisition company (SPAC) CM Life Sciences III, as it looks to accelerate its growth. 9 August 2021
US biotech BioMarin Pharmaceutical recently presented positive one-year results from its GENEr8-1 Phase III trial, in which adults with severe hemophilia A are treated with the gene therapy Roctavian (valoctocogene roxaparvovec). 9 August 2021
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) significantly improved progression-free survival in the Phase III DESTINY-Breast03 head-to-head trial versus trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. 9 August 2021
USA-based cancer specialist Epizyme today announced a collaboration with Chinese biotech Hutchmed to research, develop, manufacture and commercialize Tazverik (tazemetostat) in Greater China, including mainland China, Hong Kong, Macau and Taiwan (the Territory). 9 August 2021
The Indian subsidiary of Anglo-Swedish pharma major AstraZeneca has reported a 45.03% decline in its net profit to $1.37 million for the June ended fiscal quarter. 9 August 2021
Roche has announced a successful trial outcome with Polivy (polatuzumab vedotin), an anti-CD79b antibody-drug conjugate (ADC) currently under investigation for the treatment of several types of non-Hodgkin's lymphoma (NHL) that the company is developing using Seagen ADC technology. 9 August 2021
Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). 9 August 2021
Shares of Spectrum Pharmaceuticals fell nearly 30% on Friday, after the US oncology specialist revealed yet another delay in the approval process for its lead product candidate Rolontis (eflapegrastim). 9 August 2021
Following the announcement on Friday that the board of Vectura had accepted an improved takeover offer from private equity group Carlyle of 155 pence a share, Philip Morris has increased its previous offer for the UK inhaled medicines company. 9 August 2021